Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
Aged
Blood Glucose
/ metabolism
Diabetes Mellitus, Type 2
/ drug therapy
Drug Combinations
Fasting
/ metabolism
Female
Glycated Hemoglobin
/ metabolism
Glycemic Control
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin Glargine
/ therapeutic use
Male
Middle Aged
Peptides
/ therapeutic use
Postprandial Period
Randomized Controlled Trials as Topic
Treatment Outcome
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
accepted:
29
07
2019
pubmed:
1
8
2019
medline:
26
2
2021
entrez:
1
8
2019
Statut:
ppublish
Résumé
Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated to compare the relationship between achievement of society-recommended FPG and/or PPG targets and efficacy (HbA Across treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA Insulin glargine and lixisenatide as a fixed-ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA
Identifiants
pubmed: 31365765
doi: 10.1111/dme.14094
pmc: PMC7003844
doi:
Substances chimiques
Blood Glucose
0
Drug Combinations
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Peptides
0
hemoglobin A1c protein, human
0
Insulin Glargine
2ZM8CX04RZ
lixisenatide
74O62BB01U
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-266Informations de copyright
© 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Diabetes Spectr. 2016 Aug;29(3):152-60
pubmed: 27574369
Endocr Pract. 2006 Jan-Feb;12 Suppl 1:42-6
pubmed: 16627379
Arch Intern Med. 2004 Oct 25;164(19):2090-5
pubmed: 15505121
Diabetes Res Clin Pract. 2007 Aug;77(2):280-5
pubmed: 17240473
JAMA. 2016 Mar 1;315(9):898-907
pubmed: 26934259
Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S9-6S15
pubmed: 26774019
Diabetes Care. 2003 Mar;26(3):881-5
pubmed: 12610053
Clin Diabetes. 2018 Apr;36(2):138-147
pubmed: 29686453
Adv Ther. 2013 Feb;30(2):81-101
pubmed: 23423907
Endocr J. 2008 Aug;55(4):753-6
pubmed: 18497454
Arch Public Health. 2015 Sep 25;73:43
pubmed: 26413295
Diabetes Care. 2016 Nov;39(11):2026-2035
pubmed: 27527848
Diabetes Care. 2011 Dec;34(12):2508-14
pubmed: 22028279
Lancet Diabetes Endocrinol. 2014 Nov;2(11):911-22
pubmed: 24731666
Diabet Med. 2020 Feb;37(2):256-266
pubmed: 31365765
Endocr Pract. 2018 Jan;24(1):91-120
pubmed: 29368965
Diabetes Ther. 2017 Aug;8(4):739-752
pubmed: 28721686
Diabetes Obes Metab. 2018 Nov;20(11):2690-2694
pubmed: 29923298
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Postgrad Med. 2011 Jul;123(4):135-47
pubmed: 21680998
Diabetes Care. 2007 Feb;30(2):263-9
pubmed: 17259492
Diabetes Care. 2016 Nov;39(11):1972-1980
pubmed: 27650977
Diab Vasc Dis Res. 2006 Sep;3(2):72-9
pubmed: 17058626
Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64
pubmed: 29222377